Who are GSK Bio's influenza vaccine GSK2186877A's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): cTIV.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gsk-bio-s-influenza-vaccine-gsk2186877a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

GSK Bio's influenza vaccine GSK2186877A — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GSK Bio's influenza vaccine GSK2186877A (GSK Bio's influenza vaccine GSK2186877A) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant influenza vaccine. Area: Immunology / Infectious Disease.

phase 3 Recombinant influenza vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

GSK Bio's influenza vaccine GSK2186877A (GSK Bio's influenza vaccine GSK2186877A) — GlaxoSmithKline. GSK2186877A is a recombinant influenza vaccine designed to stimulate immune responses against influenza virus through a novel antigenic approach.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GSK Bio's influenza vaccine GSK2186877A TARGET	GSK Bio's influenza vaccine GSK2186877A	GlaxoSmithKline	phase 3	Recombinant influenza vaccine
cTIV	cTIV	Novavax	phase 3	Recombinant influenza vaccine	Influenza hemagglutinin (HA) antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant influenza vaccine class)

GlaxoSmithKline · 1 drug in this class
Novavax · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GSK Bio's influenza vaccine GSK2186877A — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk-bio-s-influenza-vaccine-gsk2186877a. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab